OTC:RGPX
REGENEREX PHARMA, INC.
A pre-revenue biopharmaceutical developer advancing novel therapies in oncology and immunology while managing significant cash burn and negative working capital.
Key Metrics
Investment Thesis
Bull Case
An investor might consider this stock if they believe in the high-potential proprietary platform and its ability to secure strategic partnerships or licensing deals that could reverse the current negative cash flow trajectory.
Bear Case
A prudent investor should avoid this stock due to the severe financial distress indicated by $-4.2M shareholders equity, negative working capital, and an inability to cover interest obligations without external financing dilution.
About REGENEREX PHARMA, INC.
Regenerex Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutic candidates to treat unmet medical needs in oncology and immunology markets. The company leverages its proprietary platform technologies to advance multiple drug candidates through preclinical and early clinical development stages. With no current product revenue, the firm relies entirely on financing activities to fund its extensive research and development pipeline.
Analysis
Management Discussion
Recent financial performance reflects a challenging pre-revenue phase with operating expenses reaching $1.8M driven by R&D costs of $662K and administrative functions of $1.2M. The company reported a net loss of $-2.5M in the latest period, exacerbated by interest expenses of $320K against minimal cash reserves relative to current liabilities of $4.9M.
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and a binary risk profile where successful candidates can generate massive returns while failures lead to total loss of invested capital.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $96.2K | $3.5M | $1.8M |
| Operating Income | $-96.2K | $-3.5M | $-1.8M |
| R&D | — | $2.4M | $662.5K |
| G&A | $96.2K | $1.1M | $1.2M |
| Stock-Based Comp | — | $211.7K | $132.7K |
| Depreciation | $3.4K | $4.3K | $3.1K |
| Amortization | $3.2K | $2.9K | $1.3K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Expense | $66.8K | $80.6K | $320.0K |
| Pre-Tax Income | $-96.2K | $-3.5M | $-1.8M |
| Income Tax | $41.2K | $78.0K | $-2.7K |
| Continuing Ops | $-137.3K | $-3.5M | $-1.8M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-137.3K | $-3.5M | $-2.5M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-137.3K | $-3.5M | $-2.5M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $1.1K | $2.9K | $653.4K |
| Cash & Equivalents | $1.1K | $372 | $653.0K |
| Other Current Assets | $0 | $2.5K | $350 |
| Long-Term Assets | $5.4K | $763.8K | $609.9K |
| Operating Leases | — | $756.3K | $604.3K |
| Other LT Assets | — | $7.4K | $5.6K |
| Total Assets | $6.5K | $766.7K | $1.3M |
| Current Liabilities | $776.8K | $3.8M | $4.9M |
| Accounts Payable | $75.1K | $116.8K | $197.7K |
| Current Leases | — | $128.3K | $181.9K |
| Other Current Liab | $575.9K | $3.5M | $4.5M |
| Long-Term Liabilities | $352.7K | $985.1K | $495.9K |
| Long-Term Debt | — | $184.2K | — |
| LT Operating Leases | — | $681.8K | $495.9K |
| Other LT Liab | — | $119.1K | $0 |
| Total Liabilities | $1.1M | $4.8M | $5.4M |
| Shareholders' Equity | $-1.1M | $-4.1M | $-4.2M |
| Paid-In Capital | $672.0K | $1.3M | $3.7M |
| Retained Earnings | $-2.1M | $-5.6M | $-8.1M |
| Total L&E | $6.5K | $766.7K | $1.3M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $-137.3K | $-3.5M | $-2.5M |
| Non-Cash Adjustments | $-22.2K | $3.0M | $720.6K |
| Working Capital Changes | $83.4K | $128.6K | $181.1K |
| Cash from Operations | $-76.2K | $-457.5K | $-1.6M |
| Cash from Investing | $-1.4K | $-6.3K | $-1.2K |
| Cash from Financing | $76.1K | $463.1K | $2.3M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-1.5K | $-763 | $652.7K |
| Beginning Cash | $2.6K | $1.1K | $372 |
| Ending Cash | $1.1K | $372 | $653.0K |
Frequently Asked Questions
How does REGENEREX PHARMA, INC. make money?
The company's operations are primarily structured around two main segments: proprietary drug development focused on oncology indications and a second stream targeting immunological disorders, both currently operating without commercial revenue streams.
What are the main risks for RGPX?
Primary risks include the complete lack of current revenue resulting in negative net income, significant cash burn exceeding operational capabilities, substantial interest expense burden relative to low liquidity, and the inherent clinical trial failure rates common in biotechnology.
What is RGPX's competitive advantage?
The company holds potential advantages through its proprietary intellectual property portfolio covering novel therapeutic mechanisms and a strategic pipeline of candidates in high-value disease areas with limited competition at early stages.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.